RA
SPRB

Rosalind Advisors’s Spruce Biosciences SPRB Stock Holding History

Rosalind Advisors’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-20,112
Closed -$781K – 43
2024
Q2 		$781K Hold
20,112
– – 0.6% 30
2024
Q1 		$1.19M Sell
20,112
-1,040
-5% -$264K 1.11% 26
2023
Q4 		$4.65M Buy
+21,152
New +$2.44M 3.83% 13

Other funds holding SPRB

RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rosalind Advisors's SPRB Position: Q3 2024 in Review

Rosalind Advisors sold out of Spruce Biosciences (SPRB) in Q3 2024, closing a stake of 20,112 shares — an estimated $781K sold.

Rosalind Advisors first reported a position in SPRB in Q4 2023 and held it in 3 quarters. The position peaked at $4.65M in Q4 2023. 29 funds tracked by Wall St. Rank hold SPRB as of Q3 2024.

  • Rosalind Advisors reported no remaining Spruce Biosciences position as of Q3 2024 after selling out during the quarter.
  • Rosalind Advisors sold 20,112 Spruce Biosciences shares in Q3 2024, an estimated $781K.
  • Rosalind Advisors first reported a position in Spruce Biosciences in Q4 2023 and held it in 3 quarters.
  • Rosalind Advisors's Spruce Biosciences position peaked at $4.65M in Q4 2023.
  • 29 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2024.

Based on Rosalind Advisors's 13F filing for Q3 2024, filed 30 Oct 2024.